The
global Next-Generation
Sequencing Services Market size is expected to reach USD 24.5
billion by 2030, according to a new report by Grand View Research, Inc. It is
expected to expand at a CAGR of 22.56% from 2023 to 2030. The
development of next-generation sequencing (NGS) technologies has revolutionized
gene sequencing in terms of reproducibility and cost savings. This has resulted
in the introduction of several advancements in NGS technology to promote its
usage in clinical labs and hospitals. Most current innovations in this field
revolve around simplifying the usage of seq-technology and making it more
sophisticated. These factors have driven the uptake of NGS services across
various end-users.
Next-generation
sequencing has progressed from research to clinical use in the last five
years. Around 14 nations have launched large-scale genome sequencing
programs, with nearly 60 million people expected to have their genome analyzed
by 2025. Conventional disease testing service providers have broadened their
portfolio with a rising trend of seq-based genetic tests. For instance, ARUP
Laboratories announced the release of new coronavirus tests in March 2022, and
IDbyDNA, Inc. partnered with another firm to introduce new coronavirus tests,
an NGS test for respiratory illnesses, to aid physicians in evaluating patients
with pneumonia and some other respiratory problems.
With
the rising trend of high throughput sequencing within the pharma and biotech
industry, there is a need for more developments to improve the speed and
convenience of high throughput seq-platforms and simplify workflows. As a
result, companies are focusing on the development of solutions to simplify the
amplification and purification of samples and starting input. In March 2022,
Illumina, Inc. announced the release of TruSigh Oncology (TSO) Comprehensive
(EU), a comprehensive diagnostic that evaluates several tumor genes and
indicators to identify a patient's cancer's individual molecular profile. The
in vitro diagnostic (IVD) kit would assist in influencing genomic decisions for
patients with cancer across Europe, with its global debut taking place first in
Europe.
Related Press
Release@ Next-Generation
Sequencing Services Market Report
List of Key Players of Next-Generation Sequencing (NGS)
Services Market
- Quest
Diagnostics Incorporated
- ARUP
Laboratories
- Applied
Biological Materials, Inc. (abm)
- Novogene Co,
Ltd.
- Azenta Life
Sciences (GENEWIZ)
- NanoString
- Illumina,
Inc.
- PacBio
- Veritas
- BGI (Beijing
Genomics Institute)
- Gene by Gene
Ltd.
- Lucigen
Corporation
Next-generation Sequencing Services Market Report
Highlights
- By service
type, human genome sequencing held the largest revenue share in 2022 owing
to greater penetration of whole genome and whole exome sequencing
- Gene
regulation services, particularly small RNA sequencing and ChIP-seq, are
anticipated to grow at a lucrative pace during the forecast period. Rising
investment in RNA sequencing is fueling the growth of gene regulation
services
- The larger
revenue share of sequencing services as compared to other workflow steps
can be attributed to an increase in the installation of sequencing
platforms. High maintenance and recovery costs of this step have also
resulted in greater revenue generation
- By end-use,
the universities and other research entities segment held the largest
revenue share in 2022 owing to the growing application of NGS technology
for cancer prognosis as well as diagnosis and major projects taken up by
academicians and universities
- North
America dominated the market in 2022 owing to higher penetration of the
technology in this region and the availability of funds to employ the
technique and derive research findings for disease targeting
- Companies
such as GENEWIZ and Novogene Corporation are engaged in offering NGS
services based on platforms from major NGS developers. Companies such as
Illumina and BGI, on the other hand, are involved in developing sequencing
instruments and offering services to research entities
- In November
2021, Novogene stated during the 44th Annual Gathering of Molecular
Biological Society of Japan (MSBJ) in Japan that they will be launching
single-cell sequencing services specifically for their Japanese customers
- GENEWIZ
scientists are assisting in identifying the NGS solution for the projects.
The NeXT Dx Test was launched by Personalis, Inc. to assist oncologists in
identifying new therapy and clinical trial choices for cancer patients
Related Reports @
Targeted DNA/RNA Sequencing Market
Next Generation Sequencing Market
Next-generation Sequencing Services Market Segmentation
Grand
View Research has segmented the global next-generation sequencing services
market on the basis of service type, workflow, end-use, and region:
NGS Services Service Type Outlook (Revenue, USD Million,
2018 - 2030)
- Human Genome
Sequencing Services
- Single Cell
Sequencing Services
- Microbial
Genome-based Sequencing Services
- Gene
Regulation Services
- Small RNA
Sequencing
- ChIP
Sequencing
- Other Gene
Regulation-based Services
- Animal &
Plant Sequencing Services
- Other
Sequencing Services
NGS Services Workflow Outlook (Revenue, USD Million, 2018
- 2030)
- Pre-sequencing
- Sequencing
- Data
Analysis
NGS Services End-use Outlook (Revenue, USD Million, 2018
- 2030)
- Universities
& Other Research Entities
- Hospitals
& Clinics
- Pharma &
Biotech Entities
- Others
NGS Services Regional Outlook (Revenue, USD Million, 2018
- 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Switzerland
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Singapore
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals, materials,
healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-95196
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
